Method for diagnosing diseases based on levels of anti-glycan antibodies
OwnerNir Dotan, Avinoam Duklerinventors
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for diagnosing Crohn's disease (CD) or anti-phospholipid Syndrome (APS) by measuring levels of antibodies to glycans in a biological sample.
Claims72
A method of diagnosing Crohn's disease in a subject, the method comprising
- providing a test sample from said subject;
- and
- determining whether at least one an anti-glycan antibody is present in said sample, wherein said at least one anti-glycan antibody is selected from the group consisting of an anti-Glc(β) antibody, an anti-Glc(β,1-4)Glc(β) antibody, an anti-Glc(β,1-3)Glc(p antibody, an anti-GlcNAc(β) 6-sulfate antibody, an anti-Dextran antibody, an anti-Xylan antibody, an anti-GlcNAc(β,1-4)GlcNAc(β) antibody, an anti-Gal 3-sulphate(β) antibody, an anti-GlcNAc(β,1-3)GalNAc(β) antibody, an anti-GlcNAc(β,1-3)Gal(β,1-4)Glc(β) antibody, an anti-Gal(β) antibody, an anti-GalNAc(α) antibody, an anti-Glc(α) antibody, an anti-Gal(β,1-6)Gal(β) antibody, and an anti-GlcNAc(β,1-6)GalNAc(α) antibody,
- wherein the presence of said antibody in said test sample indicates the subject has Crohn's disease.
A method of diagnosing Crohn's disease in a subject, the method comprising
- providing a test sample from a subject;
- and
- determining whether an anti-glycan antibody is present in said test sample, wherein said at least one anti-glycan antibody is selected from the group consisting of an IgG Glc(β,1-3)Glc(β) antibody and an IgG anti-Man(α,1-3)Man(α) antibody,
- wherein the presence of said at least one antibody in said test sample indicates the subject has Crohn's disease.
A method of differentially diagnosing Crohn's disease or inflammatory bowel disease in a subject, the method comprising
- providing a test sample from a subject;
- and
- determining whether said sample has an antibody selected from the group consisting of an
- anti-neutrophil cytoplasmic antibody (ANCA),
- IgG anti-Glc(β,1-3)Glc(β)
- IgG ASCA;
- and
- IgA ASCA,
- wherein the absence of ANCA and the presence of at least one of said IgG anti-Glc(β,1-3)Glc(β) IgG ASCA, and IgA ASCA antibodies in said test sample indicates the subject has Crohn's disease, and
- wherein the presence of at least one of said antibodies in said test sample indicates the subject has inflammatory bowel disease (IBD).
A method of differentially diagnosing Crohn's disease colitis and ulcerative colitis in a subject, the method comprising
- providing a test sample from a subject;
- and
- determining levels of at least one an anti-glycan antibody in said sample, wherein said at least one anti-glycan antibody is selected from the group consisting of
- an IgG anti-Gal(α,1-4)GlcNAc(α) antibody,
- an IgG anti-Gal(β,1-4)GlcNAc(13) antibody,
- an IgG anti-GalNAc(α) antibody,
- an IgG anti-Glc(α) antibody,
- an IgG anti-Glc(β) antibody,
- an IgG anti-GlcNAc(β,6-Sulphate) antibody,
- an IgG anti-GlcNAc(β) antibody,
- an IgG anti-GlcNAc(β,1-6)GalNAc(α) antibody,
- an IgA anti-Gal(α,1-3)Gal(β,1-4)GlcNAc(β,1-3)Gal(β,1-4)Glc(β) antibody,
- an IgA anti-Gal(α,1-4)Gal(β,1-4), Glc(β) antibody,
- an IgA anti-Gal(β) antibody,
- an IgA anti-Gal(β,1-3)[GlcNAc(β,1-6)]GalNAc(α) antibody,
- an IgA anti-Gal(β,1-3)GlcNAc(β) antibody,
- an IgA anti-Gal(β,1-6)Gal(β) antibody,
- an IgA anti-GalNAc(α) antibody,
- an IgA anti-GalNAc(β) antibody,
- IgA an anti-Glc(β) antibody,
- an IgA anti-Glc(β,1-3)Glc(β) antibody,
- an IgA anti-GlcNAc(β) antibody,
- an IgA anti-GlcNAc(β,1-3)Gal(β,1-4)Glc(β) antibody,
- an IgA anti-GlcNAc(β,1-3)GalNAc(α) antibody,
- an IgA anti-GlcNAc(β,1-4)GlcNAc(β) antibody,
- an IgA anti-GlcNAc(β,1-6)GalNAc(α) antibody, and
- an IgA anti-Xyl(β) antibody,
- wherein the presence of said at least one antibody in said test sample indicates the subject has Crohn's disease colitis.
A method for differentially diagnosing inflammatory bowel disease (IBD) or non-IBD digestive disease (NIC) in a subject, the method comprising
- providing a test sample from a subject with symptoms of NIC or IBD;
- determining if anti chitobioside (GlcNAc(β,1-4)GlcNAc(β)) carbohydrate Antibodies (ACCA) and anti-mannan (ASCA) antibodies are present in said sample,
- wherein the presence of ACCA antibodies and the absence of ASCA antibodies in said sample indicates said subject has NIC.
A kit for diagnosing Crohn's Disease, the kit comprising one or more reagents that specifically detect an antibody selected from the group consisting of an anti-Glc(β) antibody, an anti-Glc(β,1-4)Glc(β) antibody, an anti-Glc(β,1-3)Glc(β) antibody, an anti-GlcNAc(β) 6-sulfateantibody, an anti-Man(α,1-2)Man(α) antibody, an anti-Man(α,1-3)Man(α) antibody, an anti-Man(α,1-6)Man(α) antibody, an anti-Man(α) antibody, an anti-Man(α,1-3)[Man(α,1-6)]Man(α), an anti-Dextran antibody, an anti-Xylan antibody, an anti-GlcNAc(β,1-4)GlcNAc(β) antibody, an anti-Gal 3-sulphate(β) antibody, an anti-GlcNAc(β,1-3)GalNAc(β) antibody, and an anti-GlcNAc(β,1-3)Gal(β,1-4)Glc(β) antibody.
A kit for diagnosing Crohn's Disease, the kit comprising one or more reagents that specifically detect an antibody selected from the group consisting of at least one anti-glycan antibody is selected from the group consisting of
- an IgG anti-Gal(α,1-4)GlcNAc(α) antibody,
- an IgG anti-Gal(β,1-4)GlcNAc(β) antibody,
- an IgG anti-GalNAc(α) antibody,
- an IgG anti-Glc(α) antibody,
- an IgG anti-Glc(β) antibody,
- an IgG anti-GlcNAc(β,6-Sulphate) antibody,
- an IgG anti-GlcNAc(β) antibody,
- an IgG anti-GlcNAc(β,1-6)GalNAc(α) antibody,
- an IgA anti-Gal(α,14)Gal(,1-4), Glc(β) antibody,
- an IgA anti-Gal(β) antibody,
- an IgA anti-Gal(β,1-3)[GlcNAc(β,1-6)]GalNAc(α) antibody,
- an IgA anti-Gal(β,1-3)GlcNAc(β) antibody,
- an IgA anti-Gal(β,1-6)Gal(β) antibody,
- an IgA anti-GalNAc(α) antibody,
- an IgA anti-GalNAc(β) antibody,
- IgA an anti-Glc(β) antibody,
- an IgA anti-Glc(β,1-3)Glc(β) antibody,
- an IgA anti-GlcNAc(β) antibody,
- an IgA anti-GlcNAc(β,1-3)Gal(β,1-4)Glc(β) antibody,
- an IgA anti-GlcNAc(β,1-3)GalNAc(α) antibody,
- an IgA anti-GlcNAc(β,1-4)GlcNAc(β) antibody,
- an IgA anti-GlcNAc(β,1-6)GalNAc(α) antibody, and
- an IgA anti-Xyl(β) antibody.
A kit for differentially diagnosing Crohn's disease and inflammatory bowel disease in a subject, the kit comprising one or more reagents that detect an antibody selected from the group consisting of an anti-neutrophil cytoplasmic antibody (ANCA), IgG anti-Glc(β,1-3)Glc(β, IgG ASCA;
- and IgA ASCA.
A kit for differentially diagnosing Crohn's disease colitis and ulcerative colitis in a subject, the kit comprising one or more reagents that detect at least one anti-glycan antibody selected from the group consisting of an IgG anti-Gal(α,14)GlcNAc(α) antibody, an IgG anti-Gal(β,1-4)GlcNAc(β) antibody, an IgG anti-GalNAc(α) antibody, an IgG anti-Glc(α) antibody, an IgG anti-Glc(β) antibody, an IgG anti-GlcNAc(β,6-Sulphate) antibody, an IgG anti-GlcNAc(β) antibody, an IgG anti-GlcNAc(β,1-6)GalNAc(α) antibody, an IgA anti-Gal(α,1-3)Gal(β,1-4)GlcNAc(β,1-3)Gal(β,1-4)Glc(β) antibody, an IgA anti-Gal(α,1-4)Gal(β,1-4), Glc(β) antibody, an IgA anti-Gal(β) antibody, an IgA anti-Gal(β,1-3)[GlcNAc(β,1-6)]GalNAc(α) antibody, an IgA anti-Gal(β,1-3)GlcNAc(β) antibody, an IgA anti-Gal(β,1-6)Gal(β) antibody, an IgA anti-GalNAc(α) antibody, an IgA anti- GalNAc(β) antibody, IgA an anti-Glc(β) antibody, an IgA anti-Glc(β,1-3)Glc(β) antibody, an IgA anti-GlcNAc(β) antibody, an IgA anti-GlcNAc(β,1-3)Gal(β,1-4)Glc(β) antibody, an IgA anti-GlcNAc(β,1-3)GalNAc(α) antibody, an IgA anti-GlcNAc(β,1-4)GlcNAc(β) antibody, an IgA anti-GlcNAc(β,1-6)GalNAc(O) antibody, and an IgA anti-Xyl(β) antibody.
A kit for differentially diagnosing inflammatory bowel disease (IBD) or non- IBD digestive disease (MC) in a subject, the kit comprising one or more reagents that detect at least one anti chitobioside (GlcNAc(β,1-4)GlcNAc(β)) carbohydrate Antibodies (ACCA) and anti-mannan (ASCA) antibodies.
An array comprising a plurality of carbohydrate reagents that specifically detect an antibody selected from the group consisting of an anti-Glc(β) antibody, an anti-Gal(α) antibody, an anti-Glc(β,1-4)Glc(β) antibody, an anti-Glc(β,1-3)Glc(β) antibody, an anti-GlcNAc(β) 6-sulfate antibody, an anti-Man(c, 1-2)Man(α) antibody, an anti-Man(α,1-3)Man(α) antibody, an anti-Man(α,1-6)Man(α) antibody, an anti-Man(α) antibody, an anti-Man(α,1-3)[Man(α,1-6)]Man(α), an anti-Dextran antibody, an anti-Xylan antibody, an anti-GlcNAc(β,1-4)GlcNAc(β) antibody, an anti-Gal 3-sulphate(p) antibody, an anti-aGlcNAc(β,1-3)GalNAc(β) antibody, an anti-GlcNAc(β,1-3)Gal(β,1-4)Glc(β) antibody, and an anti-Gal(α,1-3)Gal(β,1-4)GlcNAc(β) antibody, wherein said reagents are attached at an addressable location on said array.
A glycan reagent for diagnosing CD, wherein said reagent specifically detects at least one anti-glycan antibody selected from the group consisting of an anti-Gal(α,1-4)GlcNAc(x) antibody, an anti-Gal(β,1-4)GlcNAc(β) antibody, an anti- GalNAc(α) antibody, an anti-Glc(β) antibody, an anti-Glc(α) antibody, an anti- GlcNAc(β,6-Sulphate) antibody, an anti-GlcNAc(β) antibody, an anti-GlcNAc(β,1-6)GalNAc(α) antibody, an anti-Gal(α,1-4)Gal(β,1-4), Glc(β) antibody, an anti-Gal(β) antibody, an anti-Gal(β,1-3)[GlcNAc(β,1-6)]GalNAc(α) antibody, an anti-Gal(β,1-3)GlcNAc(β) antibody, an anti-Gal(0,1-6)Gal(β) antibody, an anti-GalNAc(α) antibody, an anti-GalNAc(β) antibody, an anti-Glc(β) antibody, an anti-Glc(β,1-3)Glc(β) antibody, an anti-GlcNAc(β) antibody, an anti-GlcNAc(β,1-3)Gal(β,1-4)Glc(β) antibody, an anti-GlcNAc(β,1-3)GalNAc(α) antibody, an anti-GlcNAc(β,1-4)GlcNAc(β) antibody, an anti-GlcNAc(β,1-6)GalNAc(α) antibody, an anti-Xyl(β) antibody, and an anti-Xyl(α) antibody.
Dependencies are inferred from the claim text.